Clinical Trials
14 trialsNCT01164709 2019-05-15
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Swiss Cancer Institute
Phase 1 Completed
NCT01226849 2017-04-27
SGH652
Singapore General Hospital
Phase 1 Completed
NCT00538187 2015-12-04
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00671112 2015-10-28
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00082784 2014-12-23
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
National Cancer Institute (NCI)
Phase 1 Completed
NCT00791011 2014-03-05
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Amgen
Phase 1 Completed
NCT00096005 2014-02-24
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00994500 2013-07-02
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006098 2013-06-18
PS-341 in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00103272 2013-06-04
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00054483 2013-05-16
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00348985 2013-05-03
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004002 2012-11-09
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NYU Langone Health
Phase 1 Completed
NCT00006362 2011-08-03
PS-341 in Treating Patients With Advanced Cancer
Mayo Clinic
Phase 1 Completed